Development of molecular intervention strategies for B-cell lymphoma.

Development of molecular intervention strategies for B-cell lymphoma. Expert Rev Hematol. 2020 Dec 02;: Authors: Zhou W, Chen W Abstract INTRODUCTION: There are many genetic mutations involved in B-cell lymphomagenesis. These mutations contribute to the prognosis of B-cell lymphomas and can be used for diagnosis and targeted for intervention. AREAS COVERED: This review provides an overview on targeted gene therapies for B-cell lymphoma that were newly approved or are under clinical development. These include, TP53 mutations and related pathways, such as BTK inhibitors, MDM2/4 inhibitors, and XPO1 inhibitors; new drugs targeting EZH2 mutations through competitive inhibition, such as tazemetostat and GSK126; BCL-2-targeted therapeutics, including venetoclax and ABT-263; BTK, IRAK 1/4, HCK, and myddosome complex that targets the MYD88 mutation and the related pathways. In addition, we have also discusses gene mutations that have been reported as potential therapeutic targets, such as TNFAIP3, CARD11. EXPERT OPINION: The mechanisms underlying the role of several genetic mutations in lymphomagenesis have been reported, and several studies have designed and developed drugs targeting these mutations. Many of these drugs have been approved for clinical use, while several are still under clinical development. Recent studies have identified additional genetic mutations and gene targets for BCL treatment; however, effective mole...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research